The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
 
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Research Funding - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono
 
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
 
Heinz-Josef Lenz
No Relationships to Disclose
 
Sara Lonardi
No Relationships to Disclose
 
Vittorina Zagonel
No Relationships to Disclose
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)
 
M. Luisa Limon
No Relationships to Disclose
 
Ka Yeung Mark Wong
Consulting or Advisory Role - Baxalta; Baxalta; Baxalta; Baxalta; Baxalta; Baxalta; Baxalta; Baxalta
Speakers' Bureau - Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
 
Alain Hendlisz
Research Funding - Amgen; Amgen; Amgen; Amgen; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Teva; Teva; Teva; Teva
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
 
Massimo Aglietta
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); PharmaMar; PharmaMar; PharmaMar; PharmaMar
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MERCK; MERCK; MERCK; MERCK; tesaro; tesaro; tesaro; tesaro
 
Pilar Garcia-Alfonso
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Etherna; Etherna; Etherna; Etherna; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
Speakers' Bureau - Novartis; Novartis; Novartis; Novartis
Research Funding - Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
 
Andrea Spallanzani
No Relationships to Disclose
 
Dana Backlund Cardin
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals
Research Funding - Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Synta (Inst); Synta (Inst); Synta (Inst); Synta (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie
 
Tomislav Dragovich
Employment - Taiho Pharmaceutical (I); Taiho Pharmaceutical (I); Taiho Pharmaceutical (I); Taiho Pharmaceutical (I)
Research Funding - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; Berg Pharma; Berg Pharma; Berg Pharma; Berg Pharma; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Medivir; Medivir; Medivir; Medivir; Rgenix; Rgenix; Rgenix; Rgenix
 
Usman Shah
No Relationships to Disclose
 
Ajlan Atasoy
No Relationships to Disclose
 
Jean-Marie Ledeine
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; MedImmune; MedImmune; MedImmune; MedImmune; Novartis; Novartis; Novartis; Novartis; Promega; Promega; Promega; Promega; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche